Effects of Therapeutic and supra-therapeutic intravenous doses of mavoglurant (AFQ056) on the QTc interval in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2013
At a glance
- Drugs Mavoglurant (Primary) ; Moxifloxacin
- Indications Anxiety disorders; Chorea; Drug-induced dyskinesia; Fragile X syndrome; Gastro-oesophageal reflux; Parkinson's disease; Smoking withdrawal
- Focus Adverse reactions
- 19 Sep 2013 New trial record
- 31 Aug 2013 Results presented at the 11th Congress of the European Association for Clinical Pharmacology and Therapeutics.